# US 2022/0325252 A1 · Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0325252 A1
- Document ID: US20220325252A1
- Status: Published application
- Kind: A1
- Application number: 17/831,259
- Filed: 2022-06-02
- Published: 2022-10-13
- Earliest claimed: 2013-02-08
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services; The Research Foundation for The State University of New York
- Applicants: The United States of America, as Represented by the Secretary, Department of Health & Human Services; The Research Foundation for the State University of New York
- Inventors: Peter L. COLLINS; Cyril LE NOUEN; Linda G. BROCK; Ursula J. BUCHHOLZ; Joshua Marc DINAPOLI; Steffen MUELLER; Eckard WIMMER
- Web page: https://patentgrep.com/patent/US20220325252A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- C07K 14/005: from viruses
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C12N 2760/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/00062: by genetic engineering
- C12N 2760/18522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18561: Methods of inactivation or attenuation
- C12N 2760/18562: by genetic engineering
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

## Claims

### Claim 1

A recombinant polynucleotide comprising a recombinant nucleotide sequence encoding respiratory syncytial virus (RSV) proteins NS1, NS2, or both,
wherein the codon pair bias of the recombinant nucleotide sequence encoding NS1 is reduced by at least 0.05 compared to a wildtype RSV for a corresponding nucleotide sequence encoding the RSV protein, or
wherein the codon pair bias of the recombinant nucleotide sequence encoding NS2 is reduced by at least 0.05 compared to a wildtype RSV for a corresponding nucleotide sequence encoding the RSV protein, or
both.

### Claim 2 (depends on 1)

The recombinant polynucleotide of claim 1, wherein the recombinant nucleotide sequence encodes a RSV NS1 amino acid sequence, RSV NS2 amino acid sequence, or both, that is the same as the corresponding wildtype RSV amino acid sequence, or a RSV NS1 amino acid sequence, RSV NS2 amino acid sequence, or both with up to four amino acid substitutions, additions, or deletions compared to the corresponding wildtype RSV amino acid sequence.

### Claim 3 (depends on 1)

The recombinant polynucleotide of claim 1, wherein the recombinant nucleotide sequence encoding the RSV NS 1 protein is from about 75% to about 95% identical to the corresponding nucleotide sequence of SEQ ID NO: 1, or the recombinant nucleotide sequence encoding the RSV NS 2 protein is from about 75% to about 95% identical to the corresponding nucleotide sequence of SEQ ID NO: 1, or both.

### Claim 4 (depends on 1)

The recombinant polynucleotide of claim 1, wherein the protein is NS 1 and the recombinant nucleotide sequence encoding the RSV NS 1 protein is from about 75% to about 95% identical to the corresponding nucleotide sequence of the wildtype virus.

### Claim 5 (depends on 4)

The recombinant polynucleotide of claim 4, wherein the recombinant nucleotide sequence encoding the RSV NS1 protein is about 87% identical to the corresponding sequence of the wildtype virus.

### Claim 6 (depends on 1)

The recombinant polynucleotide of claim 1, wherein the recombinant nucleotide sequence encoding the RSV NS1 protein is from about 75% to about 95% identical to nucleotides 99 to 518 of SEQ ID NO: 5.

### Claim 7 (depends on 6)

The recombinant polynucleotide of claim 6, wherein the recombinant nucleotide sequence encoding the RSV NS1 protein has the sequence of nucleotides 99 to 518 of SEQ ID NO: 5.

### Claim 8 (depends on 1)

The recombinant polynucleotide of claim 1, wherein the protein is NS2 and the recombinant nucleotide sequence encoding the RSV NS2 protein is from about 75% to about 95% identical to the corresponding nucleotide sequence of the wildtype virus.

### Claim 9 (depends on 8)

The recombinant polynucleotide of claim 8, wherein the recombinant nucleotide sequence encoding the RSV NS2 protein is about 88% identical to the corresponding sequence of the wildtype virus.

### Claim 10 (depends on 9)

The recombinant polynucleotide of claim 9, wherein the recombinant nucleotide sequence encoding the RSV NS2 protein is from about 75% to about 95% identical to nucleotides 628 to 1002 of SEQ ID NO: 5.

### Claim 11 (depends on 10)

The recombinant polynucleotide of claim 10, wherein the recombinant nucleotide sequence encoding the RSV NS2 protein has the sequence of nucleotides 628 to 1002 of SEQ ID NO: 5.

### Claim 12 (depends on 1)

A recombinant genome or antigenome comprising the recombinant polynucleotide of claim 1.

### Claim 13 (depends on 12)

A method of producing a recombinant virus, comprising expressing the recombinant genome or antigenome of claim 12 in a cell.

### Claim 14 (depends on 12)

A recombinant virus having the recombinant genome or antigenome of claim 12.

### Claim 15

The recombinant virus of 14, wherein the recombinant genome or antigenome is modified to include a previously characterized RSV mutation or deletion.

### Claim 16 (depends on 14)

A composition comprising the recombinant virus of claim 14 and a physiologically acceptable carrier and/or adjuvant.

### Claim 17 (depends on 14)

A method of producing an immune response to a viral protein, comprising administering the recombinant virus of claim 14 to an animal.

### Claim 18 (depends on 17)

The method of claim 17, wherein the recombinant virus is administered via injection, aerosol delivery, nasal spray, nasal droplets, oral inoculation, or topical application.

### Claim 19 (depends on 17)

The method of claim 17, wherein the animal is a mammal.

### Claim 20 (depends on 19)

The method of claim 19, wherein the mammal is a human.
